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Abstract
Background: Lung adenocarcinoma (LAD) has extreme genetic variation among patients, which is currently not well
understood, limiting progress in therapy development and research. LAD intrinsic molecular subtypes are a validated
stratification of naturally-occurring gene expression patterns and encompass different functional pathways and patient
outcomes. Patients may have incurred different mutations and alterations that led to the different subtypes. We
hypothesized that the LAD molecular subtypes co-occur with distinct mutations and alterations in patient tumors.
Methodology/Principal Findings: The LAD molecular subtypes (Bronchioid, Magnoid, and Squamoid) were tested for
association with gene mutations and DNA copy number alterations using statistical methods and published cohorts
(n=504). A novel validation (n=116) cohort was assayed and interrogated to confirm subtype-alteration associations. Gene
mutation rates (EGFR, KRAS, STK11, TP53), chromosomal instability, regional copy number, and genomewide DNA
methylation were significantly different among tumors of the molecular subtypes. Secondary analyses compared subtypes
by integrated alterations and patient outcomes. Tumors having integrated alterations in the same gene associated with the
subtypes, e.g. mutation, deletion and underexpression of STK11 with Magnoid, and mutation, amplification, and
overexpression of EGFR with Bronchioid. The subtypes also associated with tumors having concurrent mutant genes, such
as KRAS-STK11 with Magnoid. Patient overall survival, cisplatin plus vinorelbine therapy response and predicted gefitinib
sensitivity were significantly different among the subtypes.
Conclusions/ Significance: The lung adenocarcinoma intrinsic molecular subtypes co-occur with grossly distinct genomic
alterations and with patient therapy response. These results advance the understanding of lung adenocarcinoma etiology
and nominate patient subgroups for future evaluation of treatment response.
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Lung cancer is the leading cause of cancer deaths worldwide [1]
with lung adenocarcinoma (LAD) being one of the most common
morphological varieties. Recently, reports of DNA copy number
[2–5], gene sequence mutation [2,3,6–8], DNA methylation [9],
and gene expression [2–4,6–8,10–18] have revealed LAD to be
among the most heavily mutated and genomically-altered cancers
[7]. However, few genes are commonly mutated, for example
TP53 is the most frequent at only 35% [6]. This lack of a universal
mutation pattern indicates that LAD’s molecular pathogenesis has
abundant variety. Some of this variety, such as the mutual
exclusivity of EGFR mutation and KRAS mutation has been
established and has led to therapeutic advances [6,19].
A more complete understanding of LAD’s molecular patho-
genesis is clinically-relevant because it could lead to better
application and development of targeted therapies [19,20].
Currently, targeted chemotherapy is administered to LAD patients
having a particular genomic alteration, e.g. EGFR inhibitors
(erlotinib, gefitinib) for EGFR mutant cancers [19,21]. However,
many studies have found that about 20% of patients with mutant
EGFR fail to respond to EGFR inhibitors and about 25% of
patients with wildtype EGFR receive clinical benefit from EGFR
inhibitors [22,23]. So, factors beyond one genomic alteration can
affect response to targeted therapy. Identifying these additional
factors could improve patient outcomes.
Using genome-wide gene expression profiling, LAD has been
divided into intrinsic molecular subtypes by many investigators
[3,8,10–16] including a meta-analysis by our group [14,21] in
which we named the molecular subtypes: Bronchioid, Magnoid,
and Squamoid. The subtypes represent the main naturally-
occurring patterns of LAD gene expression and separate tumors
following different functional pathways, such as proliferation in
Magnoid and development in Bronchioid. The subtypes are also
clinically-relevant, as the Bronchioid subtype predicts superior
patient survival [14]. Considering that different genomic alter-
ations in LAD mouse models cause divergent gene expression
[24], we hypothesized that tumors in different molecular subtypes
would have distinct alterations in gene sequence, DNA copy
number, and DNA methylation and combinations thereof. Beyond
preliminary reports of EGFR and KRAS sequence mutations with
subtype [2,3,16], LAD subtype-specific alterations are unknown.
Here, we detected genomic alterations co-occurring with the
LAD molecular subtypes using published discovery cohorts
[2,6,8,11]. To independently validate these associations, we
collected a novel cohort of patients with LAD (n=116) and
assayed their tumors for genome-wide gene expression, genome-
wide DNA copy number, genome-wide DNA methylation, and
selected gene sequence mutations. For the first time, we
demonstrate that LAD molecular subtypes correlate with grossly
distinct genomic alterations and patient therapy response.
Materials and Methods
Study design and published cohorts
A discovery and validation study design was followed to detect
and validate genomic alterations associated with the LAD
molecular subtypes. Published LAD cohorts assayed by gene
expression, DNA copy number or gene mutation sequencing were
acquired [2,6,8,11,17,18,25]. The details of cohort composition
and complete methodology including microarray processing are
presented in Tables S1, S2 and S3.
Tumor collection and genetic assays
Retrospective macrodissected lung adenocarcinomas from
patients receiving surgery for curative intent were collected at
the University of North Carolina at Chapel Hill (UNC) under a
waiver of consent by the UNC Biomedical Institutional Review
Board approved protocol #07-0120. Gene expression was
measured by Agilent 44 K microarrays. DNA copy number was
measured by Affymetrix 250 K Sty and SNP6 microarrays. DNA
methylation was measured by the MSNP microarray assay [26].
DNA from EGFR, KRAS, STK11 and TP53 exons were sequenced
by ABI sequencers (Table S4). Mutations were non-synonymous
or splice site differences compared to reference sequence [27].
These data were publicly deposited (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE36471).
Figure 1. Lung adenocarcinoma molecular subtype expression
characteristics. LAD subtype gene expression is displayed for all
cohorts (Bhattacharjee et al., Chitale et al., Ding et al., Shedden et al.,
Tomida et al., UNC, Zhu et al.) in which columns are tumors and rows
are genes and shading indicates gene expression level (A). Exemplar
genes are displayed separately for visualization ease (B).
doi:10.1371/journal.pone.0036530.g001
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In order to derive standardized molecular subtype assignments
for all LAD tumors in this study, molecular subtypes were detected
using gene expression as previously described [14] using Con-
sensusClusterPlus [28] and the largest published cohort, Shedden
et al. A nearest centroid subtype predictor [29] utilizing 506 genes
was trained on the Shedden et al. cohort and applied to all LAD
tumors. The subtype predictor centroids were then publically
posted (http://cancer.unc.edu/nhayes/publications/adenocarcinoma.
2012/).
Survival analysis
Patients with less than one month of follow-up time were
assumed to have surgical complications and removed from overall
survival analyses (Bhattacharjee et al., 2 patients; Shedden et al., 3
patients; UNC, 3 patients, Zhu et al., 1 patient). Because some
patients were common between the Shedden et al. and Chitale
et al. cohorts, survival and redundant clinical data were removed
from the Chitale et al. cohort. Patient disease-specific-survival was
compared by subtype and treatment in the Zhu et al. cohort [25].
Survival outcomes were estimated by the Kaplan-Meier method
and hazard ratios were estimated by Cox proportional hazards.
DNA copy number (CN) analysis
Chromosomal instability (CIN) is a per tumor genomewide
measure of CN instability. CIN was defined as the median of
chromosome arm absolute copy numbers within a tumor, similar
to published studies [30,31]. Large values represent high CIN.
DiNAMIC [32] identified regions of recurrent CN alterations in
published cohorts. Tumors were assigned their median CN across
probes within these regions. Region CNs were compared among
the subtypes by Kruskal-Wallis tests using the discovery cohorts.
For each region with significantly different CN (Benjamini-
Hochberg adjusted P,0.05), the subtype with greatest absolute
copy number (GACN) was identified by taking the subtype
partition (Bronchoid versus Magnoid and Squamoid; Magnoid
versus Bronchioid and Squamoid; or Squamoid versus Bronchioid
and Magnoid) with the greatest absolute difference in median CN,
and identifying the group farthest from zero (which is the normal
CN value). These regions and GACN subtypes were compared in
the validation cohort using Wilcoxon rank-sum tests with the null
Table 1: Subtype clinical and morphological characteristics.
Characteristic Clinical n Statistic Bronchioid Magnoid Squamoid
unique patients 1,004 total 370 360 274
Sex 989 % female 62 44 50 *
Age 771 median 65 65 64
nonsmoker 860 % 30 6 18 *
pack years 456 median 15 40 36 *
Stage 954 % I 75 59 54 *
%I I 1 4 2 4 2 0
% III 10 16 23
%I V 1 1 2
Grade 794 % well 32 11 1 *
% mod 53 49 38
% poor 15 40 61
Morphological
features
adenosquamous 230 % 4 3 18 +
bronchioloalveolar 358 % 31 13 13 *
necrosis 87 % 4 52 43 *
invasion 87 % 71 94 100 +
lymphocytes 89 % 15 9 30
percentages
papillary 41 median 51 31 0 +
acinar 41 median 40 30 20 +
solid 40 median 0 3 80 *
fibrosis 50 median 20 10 3
tumor cellularity 283 median 80 80 80
Patient characteristics are summarized over all cohorts. The number of patients having a characteristic (n) varies because all cohorts do not include all characteristics.
The percent statistics indicate the percent of tumors in a subtype having a given characteristic, e.g. 75% of the tumors in the Bronchioid subtype are stage I. The
percentage characteristics refer to percentage values given to individual tumors, and subtype median values are presented, e.g., the median papillary percentage of
tumors in the Bronchioid subtype is 51. Categorical and continuous variables were compared by Fisher’s exact tests and Kruskal-Wallis tests, respectively (*: two-sided
P,0.001; +: two-sided P,0.05). Cohort stratification was evaluated and did not change these results’ significance.
doi:10.1371/journal.pone.0036530.t001
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versus other subtypes with significant results having P,0.05.
Afterwards, all regions were compared in the validation cohort to
detect possible subtype associations not found in the discovery
cohort (Kruskal-Wallis tests, Benjamini-Hochberg adjusted
P,0.05). Human genome assembly hg 18 coordinates were used
for probe locations.
Methylation-SNP (MSNP) analysis
Methylation was measured by comparing the abundance of
DNA digested by methylation-sensitive HpaII to HpaII-undigested
DNA by Affymetrix 250 K Sty microarrays [26]. The arrays had
57,566 HpaII (methylation) sites and 169,804 control sites.
Methylation was quantified by percent change relative to the
undigested DNA abundance, (undigested – HpaII) / undigested.
Increasing values indicate increasing methylation.
Integrated genetic analyses
Several integrated analyses between molecular subtype and one
or more genetic variables were performed. For each particular
integrated analysis, all tumors with the necessary assays were
selected, normalized within their cohort, pooled and analyzed
together (details listed in Table S2).
Gefitinib sensitivity prediction
A published expression signature that predicted gefitinib
sensitivity based on baseline gene expression in non-small cell
lung cancer cell lines [33] was used to assign predicted gefitinib
sensitivity scores to tumors. The published gefitinib overexpressed
genes and underexpressed genes were combined to define a
gefitinib sensitivity score for each tumor:
X no
i~1
oiz{1 
X nu
j~1
uj
noznu
,
where o and u represent expression of the overexpressed and
underexpressed genes, respectively, and n represents the gene total.
Increasing scores indicate increasing sensitivity.
Computational procedures were executed using R (http://
www.r-project.org) and Bioconductor libraries (http://www.
bioconductor.org ) unless otherwise specified.
Results
Molecular subtype characteristics
In order to compare genomic alterations among molecular
subtypes, tumors were assigned to a lung adenocarcinoma (LAD)
molecular subtype (Bronchioid, Squamoid, or Magnoid) using
published methods (Fig. S1, S2, 1A). Consistent with earlier reports
[11,13,14], the subtypes overexpressed genes involved in distinctive
biological processes including: Bronchioid – excretion genes, asthma
genes, and surfactants (SFTPB, SFTPC, SFTPD); Magnoid – DNA
repair genes, such as thymine-DNA glycosylase (TDG); Squamoid –
defense response genes, such as chemokine ligand 10 (CXCL10)
(Fig. 1B). Confirming and extending earlier studies [11,13,14,16], the
subtypes had very different clinical profiles (Table 1). Bronchioid had
the most females, nonsmokers, early stage tumors, and low grade
tumors, the greatest acinar content, the least necrosis, and the least
invasion. Squamoid had the most high grade tumors, the greatest
solidcontent,andthelowestpapillarycontent.Magnoidhadthemost
smokers and the heaviest smokers by pack years. Bronchioloalveolar
and adenosquamous features were most prevalent in the Bronchioid
and Squamoid subtypes, respectively, consistent with their expression
similarities to these histological subclasses (Fig. S2).
Table 2: Molecular subtypes compared by gene sequence mutations.
Discovery cohorts (Bhattacharjee et al., Chitale et al., Ding et al., Tomida et al.)
Bronchioid Magnoid Squamoid P9 q-value
Subtype with greatest
mutation frequency
EGFR 37% 9% 18% 4.96610
210 3.47610
29 Bronchioid
KRAS 16% 30% 18% 0.00410 0.0113 Magnoid
TP53 22% 40% 33% 0.00484 0.0113 Magnoid
STK11 13% 22% 8% 0.0691 0.121 Magnoid
LRP1B 0% 17% 29% 0.101 0.125 -
BRAF 5% 0% 2% 0.107 0.125 -
PTEN 3% 3% 8% 0.344 0.344 -
Validation cohort (UNC)
Bronchioid Magnoid Squamoid P0 q-value
EGFR 24% 7% 6% 0.0293 0.0293
KRAS 5% 37% 15% 4.48610
24 7.95610
24
TP53 10% 58% 15% 6.40610
27 2.56610
26
STK11 3% 29% 0% 5.96610
24 7.95610
24
Percentages are the proportion of tumors having a mutation within a subtype, e.g. 37% of Bronchioid tumors have an EGFR mutation in the discovery cohorts.
Corresponding numbers of patients with gene mutations are presented in Table S5. The association of subtype and mutations in the discovery cohorts were compared
by Fisher’s exact tests on three subtypes (two-sided P9). For significantly associated genes (P9,0.10), the subtype with the greatest mutation frequency was identified
and is listed. In the validation cohort, Fisher’s exact tests evaluated the null hypothesis that each gene’s subtype with greatest mutation frequency had not greater
mutation frequency than the other subtypes (one-sided P0). Benjamini-Hochberg false discovery rates (q-values) are also displayed for the discovery and validation
cohort.
doi:10.1371/journal.pone.0036530.t002
Lung Adenocarcinoma Subtype Pathogenesis
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36530Figure 2. Molecular subtypes compared by chromosomal instability and regional DNA copy number. Chromosomal instability (CIN)
grouped by molecular subtypes is displayed for discovery cohorts with CN (Chitale et al., Ding et al.) and the validation cohort (UNC) (A). Subtype CIN
was compared by a Kruskal-Wallis test on three subtypes of the discovery cohorts (two-sided P9). A Wilcoxon rank-sum test evaluated the null
hypothesis that Magnoid had not greater CIN than other subtypes in the validation cohort (one-sided P0). Normal lung specimens’ CIN are shown for
reference. The subtype regional DNA copy number (CN) medians of the discovery cohort are displayed (B). CN values below zero indicate copy
Lung Adenocarcinoma Subtype Pathogenesis
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To determine if the molecular subtypes co-occurred with
different mutant genes, the discovery cohorts (published cohorts
with gene mutation status: Bhattacharjee et al., Chitale et al., Ding
et al., Tomida et al.) were pooled and filtered for genes in which
five or more patients had mutations (BRAF, EGFR, KRAS, LRP1B,
PTEN, STK11 and TP53). Of these, four mutant genes were
significantly associated with molecular subtype (two-sided P,0.10,
Table 2 and Table S5). Bronchioid had the greatest EGFR
mutation frequency, while Magnoid had the greatest mutation
frequencies in TP53, KRAS and STK11. To independently validate
these subtype and mutant gene associations, these four genes were
sequenced in the UNC cohort. Again, Bronchioid had a
significantly greater EGFR mutation frequency than the other
subtypes and Magnoid had greater mutation frequencies of TP53,
KRAS and STK11 than other subtypes (Table 2 and Table S5).
These results convincingly demonstrated that the LAD molecular
subtypes have distinct mutation frequencies of four genes and that
the subtypes tend to have different genes mutated.
To evaluate if the LAD molecular subtypes also have different
genomewide mutation rates, a large set of rarely mutated genes (n
=623) from the Ding et al. cohort was used to calculate
genomewide nonsynonymous mutation rates for each tumor.
Mutation rates were significantly different among the subtypes
with increasing mutation rates observed in Bronchioid, Squamoid
and Magnoid (Table S6).
Contrasting chromosomal instability and regional DNA
copy number alterations by molecular subtype
To detect DNA copy number (CN) differences among the
subtypes, the discovery cohorts (published cohorts with DNA CN:
Chitale et al., Ding et al.) were pooled and analyzed. A
chromosomal instability (CIN) statistic was calculated for each
tumor that represents the average absolute magnitude of CN
alterations over the genome. CIN values of zero indicate a
completely normal genome and increasing positive values indicate
a genome with an increasing degree of copy number alteration.
CIN was significantly different among the subtypes, with Magnoid
having the highest CIN (Fig. 2A). Again in the UNC cohort,
Magnoid had significantly greater CIN than the other subtypes;
therefore, Magnoid’s high CIN was independently validated
(Fig. 2A).
Subtype CN profiles revealed regional CN differences among
the subtypes in the discovery cohorts (Fig. 2B). To identify
standardized regions in which to compare CN, the discovery
cohorts were queried for statistically altered regions without regard
to subtype, yielding 39 regions (Table S7). Subtypes were
compared by median CN within these regions in the discovery
cohorts. 26 of the 39 regions had statistically different CN among
the subtypes (Fig. 2C). For each region, the subtype having the
greatest absolute copy number (GACN) was identified. For
example, Magnoid had GACN in region 1q21–23 (Fig. 2B,C).
For independent validation, the 26 regions and corresponding
GACN subtypes were compared in the UNC cohort. Remarkably,
in 21 regions, the subtype with GACN in the discovery cohorts
had greater absolute CN than the other subtypes in the UNC
cohort, reaching statistical significance in 7 of the 21 regions
(Fig. 2D). Afterwards, all regions were compared directly in the
validation cohort, yielding only two new subtype-associated
regions (3p26-12 and 9p24-21) indicating that the majority of
subtype-associated regions are not dependent on cohort or
platform. Overall, the subtype-associated regional CN alterations
were independently validated.
CN alterations are known to affect expression of genes residing
within altered regions across lung cancer [4], suggesting that the
subtype-specific regional CN may correlate with subtype-specific
regional gene expression. To test this hypothesis, the difference in
CN of the 26 regions and the difference in median expression of
genes residing within the regions were calculated between the
corresponding GACN subtype and other subtypes –(Fig. 3).
Regional CN difference and regional expression difference were
significantly positively correlated. In other words, the subtype with
the greatest amplification for a region also exhibited the greatest
overexpression of genes in the region, and similarly for deletion
and underexpression. Therefore, subtype-specific CN alterations
likely contribute to causing the subtype-specific gene expression
profiles.
Divergence in DNA methylation among molecular
subtypes
In addition to genetic alterations, the molecular subtypes may
have different epigenetic modulations, namely DNA methylation
alterations. Published LAD cohorts with gene expression and
DNA methylation were not available, so subtype differences were
detected directly in the UNC cohort. Over all methylation sites
genomewide, the LAD subtypes had significantly different median
methylation (Fig. 4A). Magnoid exhibited increased methylation
(‘‘hypermethylation’’) compared to other subtypes and to normal
lung.
Similar to the genomewide trend, the most differentially-
methylated sites were hypermethylated in Magnoid compared to
normal lung, followed by Squamoid and Bronchioid (Table S8).
Interestingly, the genomic positions of sites hypermethylated in
subtypes compared to normal lung showed regional variation with
a peak at 5 p (Fig. 4B). CN and methylation at 5 p were positively
related, with Magnoid tumors having the greatest values of both
CN and methylation (Fig. 4C). TERT resides in 5 p and is affected
by aberrant hypermethylation and deregulated expression in
cervical cancer [34], suggesting a target in this region for
Magnoid. Sites hypermethylated in normal lung compared to
tumors were much rarer and between-subtype site differences were
negligible and did not exhibit regional variation. Taken together,
the main methylation alteration was genomewide hypermethyla-
tion in Magnoid.
Integrated alterations among molecular subtypes
In addition to single alterations, the molecular subtypes
possessed different genes affected by integrated alterations in the
same tumors (Fig. 5). The Bronchioid subtype was distinctly
enriched with tumors having integrated mutation, CN amplifica-
tion and overexpression in EGFR. The Magnoid subtype had the
greatest prevalence of tumors with integrated mutation and CN
number deletion, at zero indicate normal copy number, and above zero indicate copy number amplification. Subtype-associated CN regions from the
discovery cohorts are displayed (C), in which the subtype with greatest absolute copy number is indicated by colored rectangle. For independent
confirmation, these regions and associated-subtypes were tested in the validation cohort, results of which are displayed (D). For example in discovery
cohorts, CN of 1q21–23 was significantly different among subtypes with Magnoid having the greatest CN (C), and in the validation cohort, Magnoid
had significantly greater absolute CN compared to other subtypes (D). Afterwards, subtypes were compared by all regions in the validation cohort
and new regions are marked by a dot (D).
doi:10.1371/journal.pone.0036530.g002
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with TP53 mutation. Interestingly, Magnoid TP53 altered tumors
also had frequent CIN, one of the consequences of mutant TP53
[35]. So, TP53 appears to be an important inactivated gene in
Magnoid; however, Magnoid had additional integrated altered
genes indicating that TP53 was not its lone gene of importance.
Tumors with integrated mutation, CN deletion and under-
expression in STK11 were most prevalent in the Magnoid subtype.
The Magnoid subtype also contained the most tumors with
integrated mutation, CN amplification and overexpression in
KRAS. In sum, the subtypes distinctively contained tumors with
integrated alterations in EGFR, KRAS, STK11, and TP53,
suggesting these genes may be subtype-specific drivers in cancer
development.
In addition to alterations targeting the same gene, concurrent
mutant gene combinations were prominent among the subtypes.
Focusing on tumors with an EGFR mutation, Bronchioids typically
had EGFR mutations as a solitary mutation and rarely concur-
rently with TP53 (Fig. S3A). Contrastingly, non-Bronchioid EGFR
mutants often also had concurrent TP53 mutations (Fig. S3A).
Remarkably among tumors having a TP53, STK11 or KRAS gene
mutation, Magnoids frequently had two of these genes concur-
rently mutated in the same tumors [ (TP53 plus STK11), (TP53
plus KRAS)o r( KRAS plus STK11)] while these combinations
occurred much less frequently in other subtypes (Fig. S3B, C, D).
Therefore, concurrent mutant gene combinations, in addition to
single mutations, may be subtype-specific drivers in cancer
development.
Patient survival and therapy response vary by molecular
subtypes
Patient overall survival was significantly different among the
subtypes, with Bronchioid having the best outcome (Fig. 6A), as
previously reported [14]. After controlling for all well-measured
possible confounders including stage, grade and age, subtype
significantly predicted overall survival.
Patient therapy response was retrospectively compared using
the Zhu et al. clinical trial cohort that included tumor gene
expression profiling prior to adjuvant treatment [25]. Patient
disease-specific survival after treatment was markedly different
among the subtypes (Fig. 6B). Specifically, only Magnoid patients
exhibited clinically and statistically significant improved disease-
specific survival compared to observation alone. In stark contrast,
Bronchioid and Squamoid patients showed no benefit. Although
the overall numbers were small, there was even a suggestion of an
inferior outcome for Bronchioid patients treated with chemother-
apy compared to observation. Possibly, Magnoid cancers are
sensitive because of DNA repair defects, similar to basal-like breast
Figure 3. Coordination of DNA copy number and gene
expression among subtypes. Each point represents one of the 26
subtype-associated copy number (CN) regions, which are colored by
the subtype having the greatest absolute copy number (GACN). The
vertical axis is the difference in median CN between the GACN subtype
and other subtypes. For the genes in each region, the differences in
median expression between the GACN subtype and other subtypes
were calculated and the median of these differences is the value on the
horizontal axis. The association of CN difference and gene expression
difference across these regions was compared by a Spearman
correlation test (two-sided P). Two example DNA regions are circled.
Region 1q21–23 had GACN in Magnoid. Hepatoma-derived growth
factor (HDGF) was one of the most Magnoid overexpressed genes in
this region. CN and gene expression for HDGF is displayed in which
each point is one tumor (B). Region 7p22-12 had GACN in Squamoid.
Fascin (FSCN1) was the most Squamoid overexpressed gene in this
region (C). For reference, black lines in (B, C) indicate median gene
expression and DNA CN. LAD tumors with copy number and expression
arrays from all cohorts were used (n=362).
doi:10.1371/journal.pone.0036530.g003
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mutations [37] and high CIN [38].
Because of its specific association with EGFR alterations
(mutation, amplification, overexpression and integrated alter-
ations), Bronchioid tumors may have the greatest sensitivity to
EGFR inhibitors. To our knowledge, there is no publically-
available clinical trial cohort with patient anti-EGFR therapy
response and gene expression. However, surrogate markers
predictive of anti-EGFR therapy response were available, including
a validated cell line expression signature of gefitinib sensitivity
[33]. Tumors were assigned gefitinib sensitivity scores using this
signature. As expected, EGFR mutant tumors had significantly
greater predicted gefitinib sensitivity than EGFR wildtype tumors
(Fig. 6C, Wilcoxon rank-sum test, one-sided P,,0.001). Addi-
tionally among EGFR tumors, Bronchioids had greater average
sensitivity scores compared to Magnoids and Squamoids. Strik-
ingly among EGFR wildtype tumors, Bronchioids had significantly
greater average sensitivity than Squamoids and Magnoids and also
had sensitivity scores similar to those of non-Bronchioid EGFR
mutant tumors. This suggests that patients with wild type EGFR
who benefit from EGFR inhibitory therapy are more likely to be in
the Bronchioid subtype than other subtypes. Moreover, this
suggests that molecular subtype may have independent predictive
value for therapy response. Although the difference in means is
statistically significant, there were small proportions of Bronchioids
with low sensitivity and non-Bronchioids with high sensitivity
indicating that subtype does not discriminate every single case.
Future studies of expression profiling and therapy response on the
same patients would be able to evaluate this directly.
Discussion
Data presented herein have shown that lung adenocarcinomas
in the intrinsic molecular subtypes have significantly different
alterations in gene sequence mutations, chromosomal instability,
regional DNA copy number, DNA methylation, and integrated
combinations. We strengthen the evidence for subtype-alteration
associations by a priori hypothesis testing in a previously-
uncharacterized cohort from our institution, which provided
substantial confidence that these associations are robust. Our
results indicate that the intrinsic, naturally-occurring molecular
subtypes are not only a gene expression phenomenon but also a
representation of different variants of LAD disease defined by
different genomic alterations.
Whether in clinical management or in laboratory models, LAD
is primarily classified by morphology, mutations, or clinical
characteristics. The LAD intrinsic molecular subtypes capture
many clinically-relevant phenotypes from these separate classifi-
cations. Bronchioid is represented by patients who are female and
nonsmoking, who have a superior survival outcome, and who
present with well-differentiated, bronchioloalveolar morphology,
early stage and EGFR mutated cancers [6,8,14,16,19,21,39]. High
smoking exposure, poor survival outcome and late-stage present-
ing patients are common in the other two subtypes: Magnoid and
Squamoid. Magnoid has a high prevalence of patients who are
male and have KRAS, TP53 or STK11 alterations [6,19].
Squamoid includes patients who present with poorly differentiated
and solid morphology cancers [6,16,40].
Figure 4: Molecular subtypes compared by DNA methylation. Genomewide DNA methylation among the three LAD subtypes were
compared by a Kruskal-Wallis test (two-sided P) in all cohorts with methylation (UNC n=33) (A). Normal lung specimens are shown for reference.
Regional variation in DNA methylation is displayed (B). For each chromosome arm, the proportion of sites hypermethylated in a subtype with respect
to normal lung is plotted. Chromosome arms with at least 4 methylation sites are displayed. Tumors’ DNA methylation and DNA copy number values
for chromosome 5 p are displayed (C).
doi:10.1371/journal.pone.0036530.g004
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insights into subtype-specific alterations. For example not only
does Bronchioid have the most EGFR mutations, this subtype also
has the most patients with integrated mutation, amplification and
overexpression of EGFR. Although this combination has been
observed [2,6,41], this is the first evidence that it predominantly
occurs in one molecular subtype. Development of the Bronchioid
subtype seems to be uniquely dependent on mutant EGFR, while
the rare EGFR mutants in other subtypes usually have concurrent
TP53 mutation. Finally, Bronchioid had the most BRAF mutants,
suggesting a second less common Bronchioid driver, although this
mutation is too rare to confirm by our analysis.
In addition to having the most TP53, STK11 and KRAS
mutations, Magnoid tumors also have severe genomic alterations
including the greatest CIN, the most regional CN alterations,
DNA hypermethylation, and the greatest genomewide mutation
rate. Magnoid’s overexpression of DNA repair genes suggests that
these tumors are actively repairing their heavily damaged genome,
possibly in response to these patients’ heavy smoke exposure.
Magnoid has the most genes with concurrent alterations in the
same patients (TP53, STK11, KRAS), unlike Bronchioid which
typically had EGFR as its sole sequence mutation as discussed
above. This again suggests that excessive DNA damage occurred
in these tumors, perhaps due to smoking exposure, and has driven
multiple gene mutations. Magnoid’s concurrency of TP53
alterations and high CIN is a novel association within an LAD
patient subgroup and could be explained by TP53 alteration
inducing high CIN, similar to recently reported cell culture studies
[35]. Finally, the Magnoid subtype exhibited increased hyper-
methylation, a phenomenon similar to the CpG-Island-Methyla-
tor-Phenotype (‘‘CIMP’’) observed in other cancers [42,43].
Lastly, the Squamoid subtype displayed the fewest distinctive
alterations that included only regional CN alterations. Adeno-
squamous features were most prevalent in Squamoid, which is the
first association with a molecular subtype to date. Squamoid had
the most PTEN mutations and loss of its locus, 10q22–q26,
suggesting this may be a Squamoid-specific driver; however, PTEN
mutation was too rare to confirm by our analysis. Interestingly, the
Squamoid subtype, which presents in patients as a poorly
differentiated solid morphology cancer and predicts poor survival,
had the fewest distinctive genomic alterations.
This study reports associations using retrospective cohorts and
determination of causation is not possible. However, because
cancers stratified by the molecular subtypes have different
genomic alterations and because genomic alterations cause cancer
[44], we infer that cancers stratified by the molecular subtypes
have arisen by different genomic alterations, so called ‘molecular
pathogenesis’. But beyond subtype and genomic alterations co-
associating in cancers, is there more to the nature of this
relationship? We offer several possible explanations. One model
Figure 5. Integrated gene alterations compared among molecular subtypes. Tumors are depicted as columns and genetic features as rows
from cohorts with CN and gene sequencing (Chitale et al., Ding et al., UNC). Gene CN’s were defined by the gene’s genomic position. The
percentages of tumors within a subtype having a given integrated combination of alterations are displayed in grey. Fisher’s exact tests on each
integrated combination and subtype were statistically significant (P,0.01).
doi:10.1371/journal.pone.0036530.g005
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that differences in genomic alterations directly cause the three
molecular subtypes we observe. Supporting evidence is provided
by mouse studies with activated cancer genes producing tumors
with varied gene expression. However, it remains unlikely that
alterations by themselves control cancer gene expression. There-
fore, an alternative model is that subtypes and alterations are both
caused by additional factors, such as the cancer’s cell type of
origin, patient behavior such as smoking, and/or patient germline
sequence. Properties of a cancer’s original cell type may promote
specific genomic alterations due to physical mutability or the
selective advantage that a specific mutation confers on a specific
cell type. Considering that lung adenocarcinoma and lung
squamous cell carcinoma have very different mutational profiles
and are believed to originate from distinct cell types [19],
differences in cell of origin seems to be a reasonable model. This
model is also supported by observations of increased EGFR
mutation prevalence in the terminal respiratory units of the lung
compared to other areas [45]. We surmise that associations
between subtypes and alterations can be explained by differences
in cell type of origin that incur different alterations, promoted by
different patient characteristics, which combined results in a
different molecular subtype and patient outcome.
The LAD molecular subtypes and their associated alterations
have clear translational significance. This study represents a
second validation of the survival advantage for the Bronchioid
subtype of LAD, a disease with few clinically implemented
biomarkers. Additionally, we present data suggesting that molec-
ular subtypes have relevance in predicting response both to
cytotoxic chemotherapy and targeted EGFR inhibitory therapy
beyond the established role of EGFR mutation status. These
observations were derived from retrospective clinical data and
surrogate response markers. Future prospective clinical trial and
model systems studies are needed to confirm and more deeply
describe the genomic basis of these findings.
In conclusion, we demonstrated that lung adenocarcinomas in
different molecular subtypes have grossly distinct genomic
alterations, clinical phenotypes, and clinical outcomes.
Figure 6. Patient outcomes compared among molecular subtypes. Overall survival is displayed for patients from cohorts with survival follow-
up (Bhattacharjee et al., Chitale et al., Shedden et al., Tomida et al., UNC, and Zhu et al.; n=807) (A). Overall survival among the three subtypes was
compared by a log-rank test (two-sided P9). Patient disease-specific-survival from the Zhu et al. JBR.10 trial 25] is displayed by treatment type, for each
subtype (B). Hazard ratios (HR) compare treatment to observation. Gefitinib sensitivity scores, derived from a cell line expression signature, are
displayed for all patients with EGFR mutation status (Bhattacharjee et al., Ding et al., Chitale et al., Tomida et al., UNC; n=561) (C). Predicted gefitinib
sensitivities were compared by Kruskal-Wallis tests among the three subtypes in the EGFR mutation group and separately for the EGFR wild type
group (two-sided P0). Wilcoxon rank-sum tests evaluated the hypothesis that Bronchioid tumors have not greater scores than Squamoid and Magnoid
tumors within each EGFR mutation group separately (one-sided P09).
doi:10.1371/journal.pone.0036530.g006
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Figure S1 Molecular subtype detection. Unsupervised
molecular subtype detection in the Shedden et al. cohort was
conducted using the top 25% most variable genes, 3,045, using
ConsensusClusterPlus [28]. The consensus matrix displays the
result for a cluster total of 3. The consensus matrix is a
symmetrical matrix of consensus values between pairs of tumors
that is indicated by blue shading. High consensus corresponds to
samples that always occur in the same cluster and is shaded dark
blue. (A). Cumulative distributions of consensus are displayed for
different cluster totals (k) (B). These were reviewed to determine
the k that first approaches the maximum consensus, which
indicates the most stable cluster total and indicates that further
increases in k are insubstantially improving consensus [28,48]. A
large increase in consensus between k=2 and k=3 was observed
(B). k=3 was near the maximum consensus distribution achieved
by greater cluster totals and the sizes of further clusters beyond 3
are small, as displayed in the item tracking plot in which tumors
belonging to the same cluster are colored the same (C). Therefore,
k=3was determined to be the most stable clustering. All pairs of
clusters in the k=3 clustering were significantly different by
SigClust [49], which tests the hypothesis that two clusters are a
result of chance alone (p-values in D). The new cluster segregated
at k=4 is not significantly different from other clusters (pink
shading in D), adding further support that the number of clusters is
3.
(PDF)
Figure S2 Comparison of molecular subtypes to histo-
logical classes. Our previously-published method of comparing
subtypes to lung histological classes using centroids was followed
[14]. Centroids for bronchioloalveolar (BAC), large cell carcinoma
(LCC), and squamous cell carcinoma (SCC) were calculated by
taking the gene-wise median as a centroid and gene-median
centering these centroids within their cohort. UNC BAC samples
are those adenocarcinomas exhibiting BAC features. Centroids for
our previous published Hayes et al. subtypes were prepared using
the Bhattacharjee et al. cohort as previously described [14]. This
study’s subtypes, from the Shedden et al. cohort, were described in
Fig. S1. Centroid similarity was assessed by Pearson correlation
coefficient using genes common among these cohorts and this
study’s subtype predictor. The correlation matrix depicts pairwise
centroid similarities, according to the scale where dark purple
represents strong gene expression similarity and dark gray
represents strong gene expression dissimilarity (B). The centroids
were clustered to determine subtype correspondences (agglomer-
ative, average-linkage, hierarchical clustering) (A). Three groups
were present in the clustering, indicated by the dendrogram and
colored squares. In these groups, the same histological classes were
grouped from the UNC and Takeuchi et al. cohorts (BAC, SCC,
and LCC), which demonstrated cross-cohort consistency. Each
group also had one member from the Hayes et al. and Shedden
et al. cohorts, indicating that the subtypes detected in this study
were consistent with the previously published Hayes et al.
subtypes. Following Hayes et al., the Shedden et al. subtypes
were named based on their unique similarities to lung histological
classes as depicted in this centroid clustering, as follows: Shedden
et al. Cluster 1–Bronchioid, Shedden et al. Cluster 2–Magnoid,
Shedden et al. Cluster 3–Squamoid. The Magnoid and Squamoid
names are reversed relative to Hayes et al. In Hayes et al., these
two names were based on similarities, which had acknowledged
subtle relationships and were based on a very small number (n=5)
of large cell carcinomas from one cohort [14]. Because this study
has 29 large cell carcinomas from two independent cohorts, the
subtype names derived by this study’s results were used in this
study. Besides this nomenclature difference, all significant results
from Hayes et al. were consistent with this study.
(PDF)
Figure S3 Gene sequence co-mutations. Tumors are
represented as columns and genes as rows. Tumors are from all
cohorts with corresponding assays (Chitate et al., Ding et al.,
UNC). Percentages of tumors within a subtype having a particular
gene mutation combination are listed. Associations of the
integrated combination with subtype were tested by Fisher’s exact
tests (P).
(PDF)
Table S1 Cohort data types and patient counts. Patients
common to Shedden et al. and Chitale et al. cohorts (n=88) and
those common to the Zhu et al. and Shedden et al. cohorts (n=43)
were counted once in the unique adenocarcinoma and lung cancer
totals. Patients common to the Tomida et al. and Takeuchi et al.
cohorts (n= 26) were counted once in the unique lung cancers
total. Gene sequencing refers to the number of tumors with at least
one gene sequenced.
(DOC)
Table S2 Study design. This table presents the order in which
steps were followed and which datasets were used. ‘X’ indicates a
cohort was used for a particular step. Separate platforms within a
cohort were gene median centered separately and merged (*).
(DOC)
Table S3 DNA copy number and methylation micro-
array processing. The copy number (CN) and methylation
microarray processing steps for each cohort are listed. ‘X’ indicates
the step was followed. Affymetrix SNP arrays were processed by
CRMAv2 [46]. The Affymetrix SNP6 microarrays were subjected
to an outlier probe removal method to remove nonhybridizations
similar to published methods [47]. Common probe locations were
calculated by taking the median of probe CN values every 2
megabases.
(DOC)
Table S4 Validation cohort gene sequencing regions.
These regions were sequenced in the UNC cohort by Polymor-
phic, Inc (Almeda CA) on ABI 3730XL DNA sequencers.
Coordinates are from human genome assembly hg 18. Regions
include some flanking intronic sequence.
(DOC)
Table S5 Subtype gene sequence mutation counts.
Numbers of patients with mutant or not mutant (wild type) genes
are listed by subtype. These numbers correspond to the
percentages in Table 2. Patient counts vary by gene because not
all cohorts sequenced all tumors for all genes.
(DOC)
Table S6 Subtype genomewide mutation rates. Non-
synonymous genome wide rates were calculated for each tumor by
diving the number of non-synonymous mutations by the number
of nucleotides sequenced. Mutation rates were significantly
different (Kruskal-Wallis test two-sided P,0.01). Confidence
intervals were calculated by 1,000 bootstrap replicates.
(DOCX)
Table S7 Regions of recurrent DNA copy number
amplifications and deletions. Regions of recurrent DNA
copy number amplifications and deletions were calculated by
DiNAMIC 32] (P,0.001). CN amplifications and deletions are
indicated by 1 and –1, respectively. For each region, marker refers
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PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36530to the point of the most extreme CN, and left and right refer to the
region’s boundaries. Positions are hg 18 genomic coordinates.
(DOC)
Table S8 Differentially methylated site totals. Cells
contain the number of sites with significantly greater methylation
in the row class compared to the column class. Methylation was
compared between classes by Wilcoxon rank-sum tests that
evaluated the null hypothesis of not greater methylation in the
row class (Benjamini-Hochberg adjusted P,0.05). For example,
11,720 sites had significantly greater methylation in Magnoid
tumors compared to normal lung. Squamoid and Bronchioid
hypermethylated sites compared to normal lung were almost
completely contained in the Magnoid versus normal sites (83%
and 88%, respectively).
(DOC)
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